Medical imaging technology company Nano-X Imaging Ltd. (NNOX:NASDAQ) Nano-X Imaging Ltd. (NNOX:NASDAQ), today announced that "it has opened its new semiconductor chip fabrication plant in South Korea." Nano-X Imaging advised that the new production facility which was opened on schedule is up and running and is now fully operational.
The company stated that the plant was built to be the primary site for producing its micro-electro-mechanical systems (MEMs) which is refers to as its Nanox.SOURCE semiconductor "chips". According to the company, "the Nanox.SOURCE chip produces the digital X-ray source for the firm's Nanox.ARC system, a 3D medical imaging system that has the potential to democratize meaningful access to imaging not currently available in approximately two-thirds of the world."
Nanox mentioned that it plans to reach targeted scaled production at the new factory in mid-2022. The firm noted that in tandem it is also gearing up its production capacity and assembly line at its Nanox.ARC system production line in Israel.
The company stated that the new South Koran fabrication plant is designed specifically to manufacture MEMs and is strategically located near what it said is the world’s largest semiconductor cluster in Yongin, S. Korea.
Nano-X Imaging explained that "its core proprietary technology is a transformation from an analog X-ray source to a digital X-ray source." The company claims that it believes its digital solution will decrease the cost of its Nanox.ARC system when compared to traditional 3D imaging systems that employ an analog X-ray source.
Nano-X Imaging's CEO Erez Meltzer commented, "Amidst a global supply chain crisis, the new facility enables Nanox to produce our own supply of semiconductor chips that are integral to the Nanox.ARC…Our new fabrication plant is an important part of our strategy of vertical integration to ensure we can deliver a global, connected medical imaging solution with the potential to meaningfully expand delivery of healthcare."
Nanox Korea's Chairman and CEO Ilung Kim Ph.D. stated, "We are proud to be opening this facility as planned, a facility that embodies our technical expertise and know-how in producing technology that we believe will revolutionize medical imaging…With our proximity to the SK Hynix semiconductor cluster, we believe we are also well-equipped to bring new, highly technical jobs to the Yongin region."
Akiva Tor, Ambassador of Israel to the Republic of Korea remarked, "Establishing a manufacturing facility in Korea is a significant move for Nanox…This is a perfect synergy of Korean investment, Israeli innovation and Korean manufacturing.”
Nano-X Imaging Ltd. is based in Neve Ilan, Israel and is involved in developing commercial-grade digital X-ray source for use medical imaging applications. The company stated that its technology could potentially deliver significant reductions in the cost of medical imaging systems.
Nano-X Imaging started the day with a market cap of around $627.7 million with approximately 51.79 million shares outstanding and a short interest of about 9.8%. NNOX shares opened 9% higher today at $13.24 (+$1.12, +9.24%) over yesterday's $12.12 closing price. The stock has traded today between $12.62 and $14.77 per share and is currently trading at $13.19 (+$1.07, +8.83%).
Disclosures
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
